BUY TATA CONSUMER PRODUCTS LIMITED — Manas Jaiswal
byManas JaiswalHorizon: NA (inferred Swing (≤2wk))8 May 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Tata Consumer Products announced its audited financial results for the quarter and year ended March 31, 2026. Revenue from operations grew 18% YoY in Q4 to Rs 5,434 Crores, and FY26 revenue rose 15% t
NSE · Press Release·8 May · 2d ago
Tata Consumer Products Limited announced its financial results for the year ended March 31, 2026. The company recommended a dividend of Rs. 10 per equity share. The financial results were audited with
NSE · Outcome of Board Meeting·8 May · 2d ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on TATA CONSUMER PRODUCTS
- BUY — HSBC Securities21 Oct 2026 · ~1 year · target ₹1,180 · Active
- BUY — Prakash Gaba15 Oct 2026 · ~2 weeks · target ₹1,020 · SL hit
- BUY — Sumeet Bagadia, Choice Broking13 Oct 2026 · ~2 weeks · target ₹990 · Target hit
- BUY — Prakash Gaba13 Oct 2026 · Same day · target ₹970 · Target hit
- BUY — Kotak Securities13 Oct 2026 · ~1 year · target ₹1,080 · Active
More from Manas Jaiswal
- BUY Ajanta Pharma23 Oct 2026 · Same day · target ₹3,425 · SL hit
- BUY Torrent Pharmaceuticals23 Oct 2026 · Same day · target ₹4,725 · SL hit
- BUY SAGILITY23 Oct 2026 · ~2 weeks · target ₹50 · SL hit
- BUY Zydus Lifesciences22 Oct 2026 · ~3 months · target ₹1,160 · SL hit
- BUY IPCA Laboratories22 Oct 2026 · ~2 weeks · target ₹2,000 · Active

